Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia <scp>A</scp>: safety and efficacy

R. Lentz, Steven; Misgav, Mudi; C. Ozelo, Margareth; Zupančić Šalek, Silva; Veljković, Dobrila; Recht, Michael; Cerqueira, M.; Tiede, Andreas; Brand, B.; Elisa Mancuso, Maria; Seremetis, Stephanie; Lindblom, Annika; Martinowitz, U.

doi:10.1111/hae.12159

Public

Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy

Published in Haemophilia • May 7, 2013

Authors:

Steven R. Lentz

Mudi Misgav

Margareth C. Ozelo

Abstract

Recombinant factor VIII (rFVIII) products provide a safe and efficacious replacement therapy for prophylaxis and treatment of bleeding episodes in patients with severe haemophilia A. This multinational, open-label, non-controlled trial investigated the safety and efficacy of turoctocog alfa, a new r...

Subject

Medicine

Haemophilia

Haemophilia A

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!